Ovarian cancer
hideOvarian cancer is a cancerous growth arising from different parts of the ovary.
The most common form of ovarian cancer (≥80%) arises from the outer lining (epithelium) of the ovary. Other forms arise from the egg cells (germ cell tumor).
In 2004, 25,580 new cases were diagnosed and 16,090 women died of ovarian cancer. The risk increases with age and decreases with pregnancy. Lifetime risk is about 1.6%, but women with affected first-degree relatives have a 5% risk. Women with a mutated BRCA1 or BRCA2 gene have a 25% risk. Ovarian cancer is the fifth leading cause of death from cancer in women and the leading cause of death from gynecological cancer.
10-year relative survival ranges from 84.1% in stage IA to 10.4% in stage IIIC.
Ovarian cancer causes non-specific symptoms, which contribute to diagnostic delay, resulting in a late stage and a poor prognosis. Most women with ovarian cancer report one or more symptoms such as abdominal pain or discomfort, an abdominal mass, bloating, back pain, urinary urgency, constipation, tiredness and a range of other non-specific symptoms, as well as more specific symptoms such as pelvic pain, abnormal vaginal bleeding or involuntary weight loss. There can be a build-up of fluid in the abdominal cavity (this is called ascites).
An abnormal physical examination (including a pelvic examination), a blood test (for CA-125, more specifically) or medical imaging studies can provide evidence leading to an ovarian cancer diagnosis. The diagnosis can be confirmed with a surgical procedure (open or keyhole surgery) to inspect the abdominal cavity, take biopsies (tissue samples for microscopic analysis) and look for cancer cells in the abdominal fluid. Treatment usually involves chemotherapy and surgery, and sometimes radiotherapy.
In most cases, the cause of ovarian cancer remains unknown. Older women, and in those who have a first or second degree relative with the disease, have an increased risk. Hereditary forms of ovarian cancer can be caused by mutations in specific genes (most notably BRCA1 and BRCA2, but also in genes for hereditary nonpolyposis colorectal cancer). Infertile women and those with a condition called endometriosis, those who have never been pregnant and those who use postmenopausal estrogen replacement therapy are at increased risk. Use of oral contraceptive pills is a protective factor. The risk is also lower in women who have had their uterine tubes blocked surgically (tubal ligation).
For more information about Ovarian cancer, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with ovarian cancer
Protein compels ovarian cancer cells to cannibalize themselves
Nov 15, 2008 |
4.5 / 5 (13) |
0
A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue ...
Cancer: The cost of being smarter than chimps?
Jun 10, 2009 |
3.7 / 5 (7) |
6
Are the cognitively superior brains of humans, in part, responsible for our higher rates of cancer? That's a question that has nagged at John McDonald, chair of Georgia Tech's School of Biology and chief research ...
Ovarian cancer's specific scent detected by dogs
Jun 26, 2008 |
5 / 5 (5) |
0
Ground-breaking research in the June issue of Integrative Cancer Therapies published by SAGE explored whether ovarian cancer has a scent different from other cancers and whether working dogs could be taught to distinguish it in ...
Trojan horse for ovarian cancer -- nanoparticles turn immune system soldiers against tumor cells
Nanotechnology / Bio & Medicine
Jul 15, 2009 |
5 / 5 (5) |
1
In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.
Nanoparticles for gene therapy improve
Nanotechnology / Bio & Medicine
Nov 06, 2009 |
5 / 5 (5) |
3
(PhysOrg.com) -- About five years ago, Professor Janet Sawicki at the Lankenau Institute in Pennsylvania read an article about nanoparticles developed by MIT's Robert Langer for gene therapy, the insertion ...
Patenting human genes thwarts research, scientists say
Jun 04, 2009 |
5 / 5 (4) |
3
Rapid advances in biology and genetics are raising fresh concerns about the spreading practice of patenting human genes.
New platinum-phosphate compounds kill ovarian cancer cells
Nov 19, 2008 |
3.8 / 5 (4) |
0
A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the ...
Found: 1 in 3 billion
Jun 11, 2009 |
5 / 5 (3) |
0
Vancouver scientists from the Ovarian Cancer Research (OvCaRe) Program at BC Cancer Agency and Vancouver Coastal Health Research Institute have discovered that there appears to be a single spelling mistake in the genetic ...
Nanoparticle-delivered 'suicide' genes slowed ovarian tumor growth (w/ Video)
Jul 30, 2009 |
5 / 5 (3) |
0
Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to ...
Multivitamin use not associated with women's risk of cancer, heart disease or death
Feb 09, 2009 |
3.3 / 5 (3) |
6
Postmenopausal women who take multivitamins appear to have the same risk of most common cancers, cardiovascular disease or dying of any cause as women who do not take multivitamin supplements, according to a report in the ...
Platypus link to ovarian cancer
Jun 26, 2009 |
5 / 5 (2) |
0
(PhysOrg.com) -- Researchers from the Royal Adelaide Hospital and University of Adelaide believe our oldest mammalian relative may help us to better understand ovarian cancer.
Cornell makes cancer vaccine for clinical use
Aug 20, 2009 |
5 / 5 (2) |
0
The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein—a cancer vaccine—that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The ...
Risk of breast cancer mutations underestimated for Asian women, study shows
Sep 11, 2008 |
5 / 5 (1) |
0
Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk ...
Investigational drug shows promise in ovarian cancer
Sep 15, 2008 |
5 / 5 (1) |
0
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical ...
Vascular marker of ovarian cancer identified
Sep 23, 2008 |
5 / 5 (1) |
0
Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth, a finding that could aid in diagnosis and treatment of ovarian cancer.
